BioAtla to Participate in the Jefferies Global Healthcare Conference
BioAtla to Participate in the Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.
聖地亞哥，2024年5月29日（GLOBE NEWSWIRE）——專注於開發用於治療實體瘤的條件活性生物製劑（CAB）抗體療法的全球臨床階段生物技術公司BioAtla, Inc.（納斯達克股票代碼：BCAB）今天宣佈，公司管理層將參加定於6月4日至4日在紐約舉行的傑富瑞全球醫療保健會議的爐邊談話和一對一投資者會議 2024 年 6 月 6 日。
Format: Fireside chat and scheduled one-on-one investor meetings
Date: Wednesday, June 5, 2024
Time: 8:00 a.m. ET
Location: New York, NY
Webcast Link: Click Here
形式：爐邊談話和預定的一對一投資者會議
日期：2024 年 6 月 5 日，星期三
時間：美國東部時間上午 8:00
地點：紐約州紐約
網絡直播鏈接：點擊這裏
About BioAtla, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 485 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company's first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit .
關於 BioAtla, Inc.
BioAtla是一家全球臨床階段的生物技術公司，通過與臨床前開發服務提供商Bioduro-Sundia的合同關係，在加利福尼亞州聖地亞哥和中國北京開展業務。利用其專有的條件活性生物製劑（CAB）技術，BioAtla開發了新型的可逆活性單克隆和雙特異性抗體以及其他候選蛋白質治療產品。與傳統抗體相比，CAB 候選產品的設計目標更具選擇性、更高的療效和更低的毒性，以及更具成本效益和更可預測的製造。BioAtla的CAB技術和產品擁有廣泛的全球專利覆蓋面，有效專利超過765項，其中超過485項是已頒發的專利。所有主要市場的專利覆蓋面廣泛，包括製造、篩選和製造CAB候選產品的方法，這些候選產品的格式和成分涵蓋了特定產品。BioAtla目前有兩個同類首創的CAB項目處於2期臨床測試中，一種是mecbotamab vedotin，一種新的條件活性AXL靶向抗體藥物偶聯物（CAB-AXL-ADC），以及一種新的條件活性ROR2靶向抗體藥物偶聯物（CAB-ROR2-ADC）ozuriftamab vedotin。2 期階段 CAB-CTLA-4 抗體 evalstotug 是一種新型 CTLA-4 抑制劑，旨在降低全身毒性，並有可能使用抗PD-1抗體等檢查點抑制劑實現更安全的聯合療法。該公司的第一款雙CAB雙特異性T細胞結合抗體 BA3182 目前處於第一階段開發階段。BA3182 靶向 epCam，EpCam 在許多腺癌上高度頻繁地表達，同時參與表達 CD3 的人類 T 細胞。要了解有關 BioAtla, Inc. 的更多信息，請訪問。
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
內部聯繫人：
理查德·沃爾德隆
首席財務官
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
外部聯繫人：
布魯斯·麥克爾
LifeSci 顧問有限公司
bmackle@lifesciadvisors.com
譯文內容由第三人軟體翻譯。